1. The past, present, and future of breast cancer models for nanomedicine development
- Author
-
Paz Boix-Montesinos, Mar Orzáez, Ana Armiñán, Paula M. Soriano-Teruel, and María J. Vicent
- Subjects
ICAM1, Intercellular adhesion molecule–1 ,PLA, Poly(lactide) ,GEMM, Genetically modified mouse model ,RAG, Rag-deficient ,02 engineering and technology ,Metastasis ,CCPM, Core-crosslinked block copolymer micelle ,TME, Tumor microenvironment ,TAM, Tumor-associated macrophages ,Breast cancer ,NIR, Near-infrared ,Th2, Type 2 T helper ,NK, Natural killer ,AGM, Aminoglutethimide ,Medicine ,NF1, Neurofibromin 1 ,BRCA1, Breast cancer type 1 susceptibility protein ,SPIO, Superparamagnetic iron oxide nanoparticle ,0303 health sciences ,education.field_of_study ,ERS1, Estrogen receptor gene ,BRCA2, Breast cancer type 2 susceptibility protein ,Organoids ,CHEK2, Checkpoint kinase 2 ,Patient-derived xenografts ,Nanomedicine ,PTBPC, Poly(2‐((tert‐butoxycarbonyl)amino)‐3‐propyl carbonate ,DOX, Doxorubicin ,0210 nano-technology ,PDOX, Patient-derived organoid-derived xenograft ,TNBC, Triple negative breast cancer ,NOG, NOD/Shi-scid/γc−/− null ,FITC, Fluorescein isothiocyanate ,Antineoplastic Agents ,2D, Two-dimensional ,MMDOX, Doxorubicin-loaded mixed micelles ,Article ,NOD-SCID, non-obese diabetic-severe combined immunodeficient ,WHO, World Health Organization ,FA, Folic acid ,PyMT, Polyoma middle tumor-antigen ,03 medical and health sciences ,HPMA, Hydroxypropyl methacrylamide ,Drug Development ,NMU, N-methyl-n-nitrosourea ,Humans ,SCID, Severe combined immunodeficient ,education ,WAP, Whey acidic protein ,Immune status ,MDR1, Multidrug resistance protein 1 ,PTEN, Phosphatase and tensin homolog ,pDNA, Plasmid desoxyribonucleic acid ,AuNR, Gold nanorod ,medicine.disease ,NP, Nanoparticle ,VIP, Vasoactive intestinal peptide ,Clinical trial ,PLGA, poly(lactide-co-glycolide) ,Nanoparticles ,HER2, Epidermal growth factor receptor 2 ,MMP, Metallopeptidases ,Th1, Type 1 T helper ,PGA, Poly-L-glutamic acid ,Biomarkers ,ROS, Reactive oxygen species ,IHC, Immunohistochemistry ,MMTV, Mouse mammary tumor virus ,IO, Iron oxide ,IONP, Iron oxide nanoparticle ,Pharmaceutical Science ,TP53, tumor protein p53 ,Bioinformatics ,ATM, Ataxia-telangiectasia mutated ,PALB2, Partner and localizer of BRCA2 ,Drug Delivery Systems ,NSG, NOD scid gamma ,uPAR, Urokinase plasminogen activator receptor ,PDNA, Plasmid DNA ,GSH, Glutathione ,LTR, Long terminal repeat ,Drug Carriers ,EPR, Enhanced permeability and retention ,PPTT, Plasmonic photothermal therapy ,TPGS, D-α-tocopheryl polyethylene glycol 1000 succinate ,DC, Dendritic cells ,HIF1α, Hypoxia-inducible factor 1 alpha ,MEF, Mouse embryonic fibroblasts ,CAF, Cancer-associated fibroblasts ,PR, Progesterone receptor ,021001 nanoscience & nanotechnology ,Nanomedicines ,Animal models ,ER, Estrogen receptor ,Nude, Athymic nude ,DMBA, 7,12-dimethylbenzantracene ,PEG, Polyethylene glycol ,Female ,MUC1, Mucin 1 ,QbD, Quality by design ,3D, Three-dimensional ,PDX, Patient-derived xenograft ,Population ,Breast Neoplasms ,Enhanced permeability and retention effect ,Pre-clinical models ,CSC, Cancer stem cells ,ALOX5, Arachidonate 5-lipoxygenase ,iPSC, induced pluripotent stem cells ,ECM, Extracellular matrix ,ComputingMethodologies_COMPUTERGRAPHICS ,030304 developmental biology ,PI3KCA, Phosphatidylinositol 3-kinase ,business.industry ,SSMM, Sterically-stabilized mixed phospholipid nanomicelle ,Cancer ,FDA, Food and Drug Administration ,PIMs, Porcine pulmonary intravascular macrophages ,EGFR, Epithelial growth factor receptor ,CDX, Cell-derived xenograft ,STK11, Serine/Threonine Kinase 11 ,business - Abstract
Graphical abstract, Even given recent advances in nanomedicine development of breast cancer treatment in recent years and promising results in pre-clinical models, cancer nanomedicines often fail at the clinical trial stage. Limitations of conventional in vitro models include the lack of representation of the stromal population, the absence of a three-dimensional (3D) structure, and a poor representation of inter-tumor and intra-tumor heterogeneity. Herein, we review those cell culture strategies that aim to overcome these limitations, including cell co-cultures, advanced 3D cell cultures, patient-derived cells, bioprinting, and microfluidics systems. The in vivo evaluation of nanomedicines must consider critical parameters that include the enhanced permeability and retention effect, the host's immune status, and the site of tumor implantation. Here, we critically discuss the advantages and limitations of current in vivo models and report how the improved selection and application of breast cancer models can improve the clinical translation of nanomedicines.
- Published
- 2021
- Full Text
- View/download PDF